Literature DB >> 15390047

Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.

Hubert H Fernandez1, Martha E Trieschmann, Michael S Okun.   

Abstract

To determine whether psychiatrically stable patients with a history of drug-induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on-going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses. (c) 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15390047     DOI: 10.1002/mds.20260

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.

Authors:  Daniel Weintraub; Howard I Hurtig
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

Review 2.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

Review 3.  Psychosis in Parkinson's disease.

Authors:  B R Thanvi; T C N Lo; D P Harsh
Journal:  Postgrad Med J       Date:  2005-10       Impact factor: 2.401

Review 4.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 6.  Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  CNS Spectr       Date:  2008-03       Impact factor: 3.790

Review 7.  The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.

Authors:  Amy T Page; Rhonda M Clifford; Kathleen Potter; Darren Schwartz; Christopher D Etherton-Beer
Journal:  Br J Clin Pharmacol       Date:  2016-06-13       Impact factor: 4.335

8.  Dementia in parkinsonism.

Authors: 
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

9.  Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?

Authors:  Thanh Phuong Pham Nguyen; Danielle S Abraham; Dylan Thibault; Daniel Weintraub; Allison W Willis
Journal:  BMC Neurol       Date:  2021-06-24       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.